La Jolla Pharmaceutical Co. (NASDAQ:LJPC) rose 4.3% during trading on Wednesday . The company traded as high as $17.21 and last traded at $17.10, with a volume of 59,769 shares trading hands. The stock had previously closed at $16.39.

LJPC has been the topic of a number of analyst reports. Lake Street Capital initiated coverage on La Jolla Pharmaceutical in a research report on Tuesday, May 24th. They set a “buy” rating and a $25.00 target price on the stock. SunTrust Banks Inc. initiated coverage on La Jolla Pharmaceutical in a research report on Wednesday, June 22nd. They set a “buy” rating and a $30.00 target price on the stock. Zacks Investment Research upgraded La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, July 12th. Finally, Jefferies Group restated a “buy” rating on shares of La Jolla Pharmaceutical in a research report on Wednesday, June 8th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. La Jolla Pharmaceutical currently has an average rating of “Buy” and a consensus price target of $39.50.

The stock has a 50 day moving average of $16.71 and a 200-day moving average of $17.50. The stock’s market cap is $318.90 million.

La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its earnings results on Friday, May 6th. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by $0.22. On average, equities analysts anticipate that La Jolla Pharmaceutical Co. will post ($3.99) earnings per share for the current year.

A hedge fund recently raised its stake in La Jolla Pharmaceutical stock. P.A.W. Capital Corp boosted its stake in La Jolla Pharmaceutical Co. (NASDAQ:LJPC) by 5.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 50,400 shares of the biopharmaceutical company’s stock after buying an additional 2,400 shares during the period. La Jolla Pharmaceutical makes up approximately 1.5% of P.A.W. Capital Corp’s holdings, making the stock its 28th largest position. P.A.W. Capital Corp owned 0.28% of La Jolla Pharmaceutical worth $1,361,000 at the end of the most recent quarter.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.